Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 100

Similar articles for PubMed (Select 24675265)

1.

Patient empowerment in the management of chronic myeloid leukemia.

Coleman M.

Clin J Oncol Nurs. 2014 Apr;18(2):E12-8. doi: 10.1188/14.CJON.E12-E18.

PMID:
24675265
2.

The challenge of the 'C' in CML.

Mauro MJ.

Leuk Res. 2014 Mar;38(3):286. doi: 10.1016/j.leukres.2013.12.003. Epub 2013 Dec 11. No abstract available.

PMID:
24439564
3.

Profiling chronic myeloid leukemia patients reporting intentional and unintentional non-adherence to lifelong therapy with tyrosine kinase inhibitors.

Efficace F, Rosti G, Cottone F, Breccia M, Castagnetti F, Iurlo A, Mandelli F, Baccarani M.

Leuk Res. 2014 Mar;38(3):294-8. doi: 10.1016/j.leukres.2013.07.003. Epub 2013 Jul 30.

PMID:
23906625
4.

How I treat newly diagnosed chronic myeloid leukemia in 2015.

Gambacorti-Passerini C, Piazza R.

Am J Hematol. 2015 Feb;90(2):156-61. doi: 10.1002/ajh.23887. Epub 2014 Nov 24. Review.

PMID:
25370814
5.

Management of the new patient with CML in chronic phase.

Marin D.

Curr Hematol Malig Rep. 2013 Mar;8(1):37-42. doi: 10.1007/s11899-012-0151-0. Review.

PMID:
23381448
6.

Targeted chronic myeloid leukemia therapy: seeking a cure.

Fausel C.

J Manag Care Pharm. 2007 Oct;13(8 Suppl A):8-12. Review.

7.

BCR-ABL kinase domain mutations, including 2 novel mutations in imatinib resistant Malaysian chronic myeloid leukemia patients-Frequency and clinical outcome.

Elias MH, Baba AA, Azlan H, Rosline H, Sim GA, Padmini M, Fadilah SA, Ankathil R.

Leuk Res. 2014 Apr;38(4):454-9. doi: 10.1016/j.leukres.2013.12.025. Epub 2014 Jan 6.

PMID:
24456693
8.

Practical advice for determining the role of BCR-ABL mutations in guiding tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia.

Jabbour E, Branford S, Saglio G, Jones D, Cortes JE, Kantarjian HM.

Cancer. 2011 May 1;117(9):1800-11. doi: 10.1002/cncr.25717. Epub 2010 Nov 29. Review. Erratum in: Cancer. 2011 Aug;117(15):3535.

9.

Disease acceptance and adherence to imatinib in Taiwanese chronic myeloid leukaemia outpatients.

Chen LC, Chen TC, Huang YB, Chang CS.

Int J Clin Pharm. 2014 Feb;36(1):120-7. doi: 10.1007/s11096-013-9867-8. Epub 2013 Oct 24.

10.

Treating chronic myeloid leukemia: improving management through understanding of the patient experience.

Simoneau CA.

Clin J Oncol Nurs. 2013 Feb;17(1):E13-20. doi: 10.1188/13.CJON.E13-E20. Review.

PMID:
23372106
11.

Association between regular molecular monitoring and tyrosine kinase inhibitor therapy adherence in chronic myelogenous leukemia in the chronic phase.

Guérin A, Chen L, Dea K, Wu EQ, Goldberg SL.

Curr Med Res Opin. 2014 Jul;30(7):1345-52. doi: 10.1185/03007995.2014.904281. Epub 2014 Mar 21.

PMID:
24640967
12.

Hematological and molecular response evaluation of CML patients on imatinib.

Gupta A, Prasad K.

J Assoc Physicians India. 2007 Feb;55:109-13.

PMID:
17571739
13.
14.

Status of leptin in MBCR-ABL p210 positive chronic myeloid leukemia patients before and after imatinib therapy: a conflicting scenario.

Bansal P, Ghalaut VS, Sharma TK, Ghalaut PS, Dokwal S, Ghalaut R, Kulshrestha M, Dahiya K.

Clin Lab. 2014;60(11):1845-52.

PMID:
25648025
16.

Kinase inhibitor therapy in CML: it's what's inside that counts.

Eide CA, Druker BJ, O'Hare T.

Oncotarget. 2013 Sep;4(9):1332-3. No abstract available.

17.

Quality of life of chronic myeloid leukemia patients in Brazil: ability to work as a key factor.

Hamerschlak N, de Souza C, Cornacchioni AL, Pasquini R, Tabak D, Spector N, Steagall M.

Support Care Cancer. 2014 Aug;22(8):2113-8. doi: 10.1007/s00520-014-2196-1. Epub 2014 Mar 20.

PMID:
24647489
18.

PD166326, a novel tyrosine kinase inhibitor, has greater antileukemic activity than imatinib mesylate in a murine model of chronic myeloid leukemia.

Wolff NC, Veach DR, Tong WP, Bornmann WG, Clarkson B, Ilaria RL Jr.

Blood. 2005 May 15;105(10):3995-4003. Epub 2005 Jan 18.

19.

Adherence to tyrosine kinase inhibitor therapy for chronic myeloid leukemia: a Brazilian single-center cohort.

de Almeida MH, Pagnano KB, Vigorito AC, Lorand-Metze I, de Souza CA.

Acta Haematol. 2013;130(1):16-22. doi: 10.1159/000345722. Epub 2013 Jan 25.

PMID:
23363706
20.

Which method better evaluates the molecular response in newly diagnosed chronic phase chronic myeloid leukemia patients with imatinib treatment, BCR-ABL(IS) or log reduction from the baseline level?

Qin YZ, Jiang Q, Jiang H, Li JL, Li LD, Zhu HH, Lai YY, Lu XJ, Liu YR, Jiang B, Huang XJ.

Leuk Res. 2013 Sep;37(9):1035-40. doi: 10.1016/j.leukres.2013.06.003. Epub 2013 Jun 26.

PMID:
23810191
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk